A Comprehensive Vision for Intravenous Iron Therapy

American Journal of Kidney Diseases

Volumn 52, Issue 6 SUPPL. 1, 2008, Pages

  Coyne, Daniel W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anemia of chronic kidney disease; erythropoiesis stimulating agent; Intravenous iron; serum ferritin

Indexed keywords

ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; IRON; IRON DEXTRAN; IRON SACCHARATE; TRANSFERRIN;

ANEMIA; BIOAVAILABILITY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; FERRITIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; PROTEIN SYNTHESIS; REVIEW;

ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FERRITINS; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; TRANSFERRIN;

EID: 55749098626     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.09.003     Document Type: Review

References (24)

1. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102 (2003) 783-788
2. Małyszko J., Małyszko J.S., Hryszko T., Pawlak K., and Mysliwiec M. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients?. Am J Nephrol 25 (2005) 586-590
3. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
4. Wish J.B. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1 suppl 1 (2006) S4-S8
5. Kalantar-Zadeh K., Rodriguez R.A., and Humphreys M.H. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19 (2004) 141-149
6. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37 suppl 1 (2001) S182-S238
7. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 suppl 3 (2006) S11-S145
8. Sunder-Plassmann G., and Hörl W.H. Erythropoietin and iron. Clin Nephrol 47 (1997) 141-157
9. Kopelman R.C., Smith L., Peoples L., Biesecker R., and Rizkala A.R. Functional iron deficiency in hemodialysis patients with high ferritin. Hemodial Int 11 (2007) 238-246
10. Lin J.L., Chang M.Y., Tan D.T., and Leu M.L. Short-term small-dose intravenous iron trial to detect functional iron deficiency in dialysis patients. Am J Nephrol 21 (2001) 91-97
11. Tarng D.C., Huang T.P., Chen T.W., and Yang W.C. Erythropoietin hyporesponsiveness: From iron deficiency to iron overload. Kidney Int Suppl 69 (1999) S107-S118
12. Aronoff G.R. Safety of intravenous iron in clinical practice: Implications for anemia management protocols. J Am Soc Nephrol 15 suppl 2 (2004) S99-S106
13. Fishbane S., Kowalski E.A., Imbriano L.J., and Maesaka J.K. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7 (1996) 2654-2657
14. Mittman N., Sreedhara R., Mushnick R., et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 30 (1997) 912-922
15. Low C.L., Bailie G.R., and Eisele G. Sensitivity and specificity of transferrin saturation and serum ferritin as markers of iron status after intravenous iron dextran in hemodialysis patients. Ren Fail 19 (1997) 781-788
16. Singh A.K., Coyne D.W., Shapiro W., Rizkala A.R., and DRIVE Study Group. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 71 (2007) 1163-1171
17. Coyne D.W., Kapoian T., Suki W., et al., DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007) 975-984
18. Gotloib L., Silverberg D., Fudin R., and Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 19 (2006) 161-167
19. Richardson D., Bartlett C., and Will E.J. Optimizing erythropoietin therapy in hemodialysis patients. Am J Kidney Dis 38 (2001) 109-117
20. Centers for Medicare & Medicaid Services. 2006 Annual Report, End-Stage Renal Disease Clinical Performance Measures Project (2007), Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards and Quality, Bethesda, MD
21. Fishbane S., Frei G.L., and Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26 (1995) 41-46
22. Sepandj F., Jindal K., West M., and Hirsch D. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11 (1996) 319-322
23. Sunder-Plassmann G., and Hörl W.H. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10 (1995) 2070-2076
24. Taylor J.E., Peat N., Porter C., and Morgan A.G. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11 (1996) 1079-1083